Expert Perspectives on Investigational PDE4 Inhibitors in Psoriasis

Patients currently benefit from apremilast as an established PDE4 inhibitor for psoriasis treatment across all severity levels, but newer agents aim to enhance efficacy while maintaining favorable safety profiles. Second-generation PDE4 inhibitors, such as orismilast, represent an advancement in oral treatment options for patients seeking improved therapeutic outcomes. These newer agents target the same trusted mechanism while striving to deliver enhanced clinical benefits for patients with moderate to severe disease.

Health care providers report comfort with the PDE4 inhibitor pathway based on extensive clinical experience and established safety data that patients can trust. The dermatology community recognizes PDE4 inhibition as a reliable therapeutic approach with well-characterized safety profiles that patients have used successfully for years. This familiarity provides confidence for both patients and providers when considering newer PDE4 inhibitor options as they become available.

Clinical trial data for orismilast demonstrate PASI 75 response rates reaching approximately 50% in phase 2 studies, representing meaningful improvement for patients compared with earlier PDE4 inhibitors. These enhanced efficacy rates suggest patients may achieve superior outcomes with next-generation PDE4 inhibitors while maintaining the safety and tolerability profiles they expect from this medication class. Patients seeking oral treatment options may benefit from these advances in PDE4 inhibitor development as new agents progress through clinical development.